Interestingly, molecular studies of the tumours revealed an ultra-mutated tumour phenotype with mutational signatures of both PMS2 and POLD1, suggesting that these factors interacted to cause the relatively severe clinical phenotype in these cases. This evidence concerns the gene PMS2 and neoplasm.